Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)

Completed

• Conditions: Rejection Chronic Renal; Renin-Angiotensin System; Rejection Acute Renal; Renal Transplant; Rejection of Renal Transplant

• Registration Number: NCT03317925
• Lead Sponsor: Wake Forest University Health Sciences

Brief Summary

In pediatric kidney transplant patients, rejection, medication toxicity and ischemia cause early and chronic renal allograft injury, which reduces graft lifespan and patient survival. Early detection of injury would facilitate prevention and treatment. The gold standard surveillance biopsy has limitations including delayed discovery of injury. No noninvasive test identifies graft injury before it is clinically apparent. This project's goal is to develop a novel early marker of subclinical graft injury to facilitate prompt recognition and treatment.

Detailed Description

Kidney damage activates the traditional renin-angiotensin (Ang) system (RAS), characterized by Ang-converting enzyme (ACE)/Ang II/Ang II type 1 receptor. The Ang-converting enzyme 2 (ACE2)/Ang-(1-7)/Mas pathway counteracts this damage. The balance, or ratio, between levels of the ACE/Ang II and ACE2/Ang-(1-7) pathways may be clinically important because Ang-(1-7) counteracts Ang II-mediated injury. An increase in ACE and Ang II expression and a decrease in ACE2 and Ang-(1-7) expression on tubular cells may promote renal injury. Tubular damage may increase urinary loss of protective ACE2 and Ang-(1-7), propagating renal damage by allowing ACE and Ang II to stimulate inflammation and fibrosis unopposed. The investigators hypothesis is that a shift in the urinary ACE-to-ACE2 and Ang II-to-Ang-(1-7) ratios towards ACE2 and Ang-(1-7) predicts acute graft injury diagnosed on renal biopsy and predicts chronic graft damage on renal biopsy.

Study Timeline

• Study Start: 2014-07-16
• Primary Completion: 2016-01-20
• Study Completion: 2017-04-26
• Status Verified: 2017-10
• Study First Submitted: 2017-10-18
• Study First Submitted QC: 2017-10-18
• Study First Posted: 2017-10-23
• Last Update Submitted: 2017-11-06
• Last Update Posted: 2017-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Ages 1 - 20 years
• Actively listed on the transplant list at Lucile Packard Children's Hospital at Stanford and received a renal transplant during the study enrollment period

Read More

Exclusion Criteria

• Transplanted at a center other than Lucile Packard Children's Hospital at Stanford

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acute graft injury	Within six months after kidney transplant	Renal biopsy-confirmed acute renal allograft injury as determined by a pathologist (binary yes or no)

Secondary Outcome Measures

Name	Time	Method
Renal function	Within six months after kidney transplant	Glomerular filtration rate by the Schwartz equation (mL/min/1.73 m\^2)
Chronic graft damage	Six months after kidney transplant	Renal biopsy-confirmed chronic renal allograft damage as determined by a quantitative fibrosis pathology stain (percent fibrosis from 0 to 100%)
Proteinuria	Within six months after kidney transplant	Urine protein-to-creatinine ratio above 0.2 mg/mg creatinine

Trial Locations

Locations (1)

Wake Forest University Baptist Medical Center; 🇺🇸 Winston-Salem, North Carolina, United States